Autoimmune and severe inflammation
HBM contact: Dr Ivo Staijen
Company status: public
biotech pioneering and advancing treatments for severe inflammation and
autoimmune diseases by selectively targeting shared critical pathways that are
the root cause of disease.
Viela’s lead asset is inebilizumab, a breakthrough treatment for Neuromyelitis
optica syndrome spectrum disorder patients.